Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Interview: KaNDy Menopause Therapy Hits Sweet Spot

NT-814 Set For Phase III Trials

Executive Summary

Prospective partners will be impressed by data which shows that the UK company's once-daily oral treatment reduces hot flashes and night sweats and has also shown very rapid improvements in mood and sleep.

You may also be interested in...



Bayer Backs Hot Flashes Drug For Blockbuster Status

The menopause drug elinzanetant, which has just gone into Phase III, has joined Kerendia, Verquvo and Nubeqa as a candidate that Bayer believes has a peak sales potential of more than €1bn.

GSK Spin-Off Launches KaNDy To Tackle Key Symptoms Of Menopause

NeRRe Therapeutics has set up a new entity around a drug which it believes could be an effective alternative to hormone replacement therapy for hot flashes that may rapidly reduce debilitating sleep disturbance.

GSK Prevents UK Strike With Improved Pay Deal

GlaxoSmithKline has averted a strike at its sites across the UK after an improved pay offer was accepted by workers.

Topics

Related Companies

UsernamePublicRestriction

Register

SC141461

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel